BVT 3498

Drug Profile

BVT 3498

Alternative Names: AMG 331

Latest Information Update: 09 Sep 2005

Price : $50

At a glance

  • Originator Biovitrum
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action 11-beta hydroxysteroid dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 08 Sep 2005 Discontinued - Phase-II for Type-2 diabetes mellitus in Sweden (unspecified route)
  • 08 Sep 2005 Discontinued - Phase-II for Type-2 diabetes mellitus in Finland (unspecified route)
  • 24 Aug 2005 This compound is still in active development - (BIO-2005)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top